key: cord-0979324-9tzirvoq
authors: Huang, Jessica; Yuen, Daniel; Mintern, Justine D.; Johnston, Angus P.R.
title: Opportunities for Innovation: Building on the success of lipid nanoparticle vaccines
date: 2021-05-29
journal: Curr Opin Colloid Interface Sci
DOI: 10.1016/j.cocis.2021.101468
sha: c97e7e238c3d55652309dfedde6aebd89399e6a4
doc_id: 979324
cord_uid: 9tzirvoq

Lipid nanoparticle (LNP) formulations of messenger RNA (mRNA) have demonstrated high efficacy as vaccines against SARS-CoV-2. The success of these nanoformulations underscores the potential of LNPs as delivery system for next generation biological therapies. In this article, we highlight the key considerations necessary for engineering LNPs as a vaccine delivery system and explore areas for further optimisation. There remain opportunities to improve protection of mRNA, optimise cytosolic delivery, target specific cells, minimise adverse side effects and control release of RNA from the particle. The modular nature of LNP formulations and the flexibility of mRNA as a payload provide many pathways to implement these strategies. Innovation in LNP vaccines is likely to accelerate with increased enthusiasm following recent successes, however any advances will have implications for a broad range of therapeutic applications beyond vaccination such as gene therapy.

Nanoparticle delivery systems have shown significant promise for therapeutic delivery, and in 2020 they delivered on this potential. The first two vaccines approved for immunisation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were lipid nanoparticle (LNP) formulations of messenger RNA (mRNA) [1] . These new nanoparticle formulations proved to be more effective and faster to develop than traditional vaccination approaches. While the first LNP formulation containing anti-sense RNA oligonucleotides was licensed in 2018, recent improvements in lipid formulation, nucleic acid chemistry and a global pandemic have accelerated the adoption of longer but more fragile mRNA cargoes.

Unlike traditional vaccines they contain no viral components and use technology developed for gene therapy to direct production of antigens by cells at the inoculation site. The recent success of these formulations highlights the growing potential of nanotherapeutics, and in particular LNP technology, as the delivery system for the next generation of biological therapies. Importantly, the accelerated approval of these nano formulations has simplified the path for developing other LNP delivery systems for the treatment of a wide range of diseases, from cancer to diabetes and cystic fibrosis.

LNPs are typically 80-200 nm in diameter [2] and are composed of nucleic acids complexed with lipids, which protect the fragile nucleic acid cargo. LNPs spontaneously self-assemble when the appropriate ratio of lipids and nucleic acids are mixed, typically with the aid of a microfluidic micromixer device. Microfluidic devices are capable of rapid and efficient mixing of the LNP components to generate LNPs with controlled size [3] . By altering the mixing conditions, type and proportion of each lipid used in the formulation, the properties of an LNP can be tuned to meet different requirements. An overview of typical LNP J o u r n a l P r e -p r o o f compositions is discussed in section 3. After assembly, dialysis is used to remove the solvents used to solubilise the lipid component. The size and polydispersity of LNPs is typically characterised by dynamic light scattering (DLS) or nanoparticle tracking analysis (NTA) . Zeta potential measurements are also used to estimate the optimal ratio of lipid to nucleic acids [4] . The dialysis step typically only removes solvent and does not remove free DNA/RNA, so it is important to characterise the encapsulation of the cargo. The encapsulation efficiency of nucleic acids is typically determined using a RiboGreen assay [5] .

Despite the remarkable effectiveness of LNPs as vaccines, they are a relatively novel technology, and many gaps remain in our knowledge of these systems. Therefore, there is considerable scope to improve the effectiveness of LNPs. Presently, lipid nanoparticleencapsulated mRNA (mRNA/LNP) vaccines require cold chain storage (< -20ºC), which has delayed the widespread distribution of the vaccines and limits their deployment in countries with less developed infrastructure. The RNA cargo of these vaccines is transcribed into protein in the cytosol, however the efficiency of delivering RNA to the cytosol once a cell has taken up an LNP is estimated to be as low as 1% [6] . Improving this efficiency at the cellular level could reduce the number of LNPs required per dose. Maximising the potency of LNP vaccines could enable the production of a larger number of smaller doses, lowering cost, increasing access and limiting the side effects of excipients included in the formulation.

There is also a need to investigate the tolerability of the lipids used to formulate LNPs.

Cationic lipids are known to exhibit cytotoxicity and there is the potential to raise an undesirable immune response against polyethylene glycol (PEG) coatings on LNPs. The future use of LNPs as a platform for delivery of different vaccines and other gene therapies could be compromised if repeated administration is not tolerable.

In this article we highlight the key parameters for engineering LNP vaccine delivery systems and examine the properties of LNPs that have made them an innovative vaccine format with significant potential for further improvement and customisation ( Figure 1 ). We focus on efforts to improve the immune response by incorporating adjuvating activity (Section 4) and optimising the antibody response (Section 5). From the materials delivery perspective, we explore strategies for increasing transport of RNA to the cytosol (Section 6), controlling release of RNA from LNPs (Section 7) and targeting LNPs to antigen presenting cells (Section 8). Finally, we look at efforts to improve the tolerability of LNPs (Section 9) and examine the implications for other applications of LNPs in light of their success as vaccines. To initiate these adaptive responses, antigen from the site of vaccine inoculation must be processed into a format recognised by T cells. The presence of local inflammation (induction of cytokines) and pathogen-identifying molecular patterns (e.g. viral nucleic acids vs bacterial lipids) modify the type and magnitude of adaptive response required. These operations are performed by tissue-resident immune surveillance cells known as antigen presenting cells (APCs) such as dendritic cells (DCs), macrophages and monocytes. After capturing and recognising antigen, APCs can migrate to the local lymph node where they encounter T and B cells and direct the development of the subsequent immune response. The components of a vaccine are chosen to manipulate the development of immunity through this mechanism.

Anti-viral vaccines vary in complexity from live attenuated viruses, to inactivated viruses, virus-like particles, through to purified recombinant proteins. Their complexity loosely reflects a balance between safety and effectiveness, however modern developments are starting to disrupt this relationship. Live attenuated vaccines are able to infect cells and replicate, producing the strongest immunogenic signals by causing inflammation, cell death or injury, but can also result in reduced tolerability which restricts use in individuals with New vaccine technologies that use genetic material lie between these extremes and have features of both. These vaccines deliver nucleic acids to cells in the body rather than directly delivering protein antigens. Once inside cells, these nucleic acids are translated into protein antigens by cellular machinery, which can subsequently be presented to the immune system.

Notably, nucleic acids are a consistent and biochemically defined payload, regardless of the proteins encoded in their sequence. An effective lipid formulation can therefore be adapted to deliver other genetically encoded antigens with minimal re-optimisation. This property provides a method to rapidly tailor these vaccines to address different viruses, as well as escape mutations that may arise in circulating strains by simply updating the coding sequence.

The main challenges of using nucleic acids as vaccines relate to their structure and function.

Unlike protein antigens, long protein-encoding nucleic acids are highly labile and rapidly degraded by nucleases present in vivo and in the general environment. Single-stranded nucleic acids such as mRNA are particularly fragile, as cleavage of a single phosphodiester bond will interrupt the coding sequence. Furthermore, mRNA is a highly negatively charged macromolecule (>500,000 Da) unable to diffuse through cell membranes. To be active, the mRNA must be transported into the cytosol where it can access cellular machinery (e.g. ribosomes) to be translated into protein. Overcoming these issues by using effective delivery systems is key to the development of nucleic acid vaccines. The disadvantage of this approach is that the viral vector itself can elicit an immune response, potentially clearing the vector before it has a chance to deliver its mRNA cargo, and limiting the re-administration of vaccines formulated in a similar vector.

Delivery of synthetic mRNA requires a different approach. To protect the mRNA from degradation and to improve cytosolic delivery, the most well-studied non-viral delivery systems are LNPs. LNPs are employed in Moderna's (MRNA-1273) and Pfizer/BioNTech's (BNT162b2) SARS-CoV-2 vaccines, which are authorised for conditional/emergency use by major regulatory agencies such as the FDA and EMA [8, 9] . A standard LNP formulation is composed of ionizable cationic lipids, PEGylated lipids, structural lipids, and cholesterol ( Figure 3 ). Cationic lipids play multiple roles in the mRNA/LNP system. During formation of LNPs, the positively charged lipids complex with negatively charged mRNA molecules [10] .

This electrostatic interaction is responsible for the high encapsulation efficiency of mRNA (and other nucleic acids) into LNPs. They also facilitate intracellular delivery of the cargo to the cytoplasm of cells by inducing endosomal escape (see Section 6) [11] . Cationic lipids can also function as adjuvants due to their immunogenicity (see Section 4) [12] . PEGylated lipids provide a hydrating 'stealth' layer to improve colloidal stability. Structural lipids contribute to the formation of the lipid bilayer and often resemble endogenous cell membrane lipids. Current SARS-CoV-2 LNP vaccines already encode engineered antigens such as the prefusion stabilised spike mutant [15] , but future iterations could include T helper epitopes derived from other coronavirus proteins, or additional spike mutants covering escape mutations observed in circulation. Future approaches could even implement protein engineering techniques used to produce more complex forms of antigen used in some subunit and virus-like particle vaccines. Presentation of antigenic proteins in a multimeric format can help to crosslink B cell receptors and enhance B cell activation [16] .

J o u r n a l P r e -p r o o f mRNA is very susceptible to chemical degradationit undergoes oxidation with reactive oxygen species (ROS) [17] , hydrolytic cleavage of the phosphodiester bond (catalysed by metallic complexes or nucleases) [18] , and internal phosphoester transfer (catalysed by RNAse A and ribozymes) [19, 20] . Chemical and sequence modifications have been used to stabilise mRNAs, with artificial 5' cap analogues, nucleobases such as 5-methylcytosine and pseudouridine, and secondary sequence structures providing protection from nuclease degradation while preserving function [21] [22] [23] . Condensation with cationic lipids can also provide some protection for mRNA, though the extent of this protection is lipid-dependent Due to the novelty of these formulations, stability data is scarce and ongoing studies are investigating if the formulations may stable at higher temperatures [9] . Additional stability data has recently (as of writing) been submitted to regulatory authorities demonstrating shortterm stability of the Pfizer/BioNTech vaccine at -20℃ (Pfizer; URL: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submitcovid-19-vaccine-stability-data). Modifying other nanoparticle components can potentially improve protection of mRNA. The choice of ionisable lipid alters the protection afforded to mRNA, though it is not yet known which properties are required for maximum protection.

Optimising each component of the carrier system can improve the stability of the system, further enabling its ability to shield mRNA from degradation. Many of these protective strategies, while discussed in the context of mRNA, are also applicable to other nucleic acids.

Vaccine development beyond initial live-attenuated and whole-pathogen formulations was driven by a need to reduce the reactogenicity and adverse effect profiles of the treatments.

However, in purifying the antigen from other viral matter to improve tolerability, the resulting vaccines had notably decreased effectiveness [24] . In order to restore the immunogenicity of these safer vaccines, adjuvants must be added to the formulation.

Adjuvants enhance activation of APCs to amplify the subsequent T and B cell responses. This is particularly important for long term protection as only a minor proportion of a de novo T and B cell response is directed to differentiate into specialised long lived memory phenotypes [25, 26] . Potent short term immune responses prevent reinfection (weeks to months), however this protection wanes and subsequent encounters require a 'recall' response (years to decades) mediated by memory cells. Increasing the magnitude of the initial response increases the number of memory cells and therefore the longevity (population halflife) of their protection. Adjuvants also substitute for pathogen associated molecular patterns (PAMPs) that identify distinct pathogens (e.g. viral double-stranded RNA, bacterial lipids) [27] . The class of PAMP detected by APCs directs the type of response raised in T and B cells ( Figure 4) . For anti-viral responses, the desirable outcome is a 'T helper 1' (T H 1) bias, characterised by antibody class switching in B cells, generation of cytotoxic CD8+ T cells and CD4+ helper T cells producing cytokines such as interferon gamma. These features are important for clearance of intracellular pathogens [28] . Lastly, adjuvants such as Alum can provide a 'depot' for gradual release of antigen over time [29] which allows B cell affinity maturation, a process which increases the potency of antibodies [30] . The presently licensed SARS-CoV-2 LNP vaccines are not formulated with conventional adjuvants. Instead, the presence of extracellular RNA and/or contaminating double-stranded RNA produced during manufacturing act as PAMPs [31] and they are often described as 'self-adjuvanting' [32] . However, the cationic lipids from LNPs are also speculated to provide a non-specific adjuvating effect through inflammation caused by cellular toxicity.

Necrotic cell death, cell stress or injury can cause release of intracellular components such as histones and heat shock proteins. These normally sequestered molecules can be recognised by APCs through pattern recognition receptors in the same manner as PAMPs. These damageassociated molecular patterns (DAMPs) can similarly activate APCs [33] and may explain the ability of LNP vaccines to function without specific adjuvants. TriMix, for example, encodes immunostimulatory receptors that can increase activation of immune cells [36] . All of these strategies would only be desirable in APCs, therefore such LNPs would ideally be targeted to specific cells (see Section 8). In the future, such vaccines could become in situ dendritic cell gene therapies, with no requirement of bystander cells and substantially fewer side effects following administration.

Antibodies play a key role in removing circulating virus through a number of mechanisms.

One type of antibody that can be generated is the neutralising antibody, which can directly inactivate virions by interfering with the function of the bound protein (Figure 5a ). SARS-J o u r n a l P r e -p r o o f CoV-2 virions can be neutralised by antibody binding to the receptor binding domain of the viral spike protein, which blocks its interaction with the cellular entry receptor on human cells and prevents infection [37] . Raising a high titre, virus-specific neutralising antibody response is the primary objective for most prophylactic vaccines.

Non-neutralising antibodies can also be beneficial against viruses and may provide broader protection against disease. Antibodies that recognise and bind to viral proteins can direct their destruction and clearance by other elements of the immune system (opsonisation - Figure 5b ). Although rare, a concern regarding vaccines is the generation of aberrant antibody responses.

A small number of viruses such as Dengue and Zika [39] are naturally capable of infecting and/or replicating in Fc-receptor expressing cells such as macrophages, which can lead to viral replication in these cells and immune dysfunction (Figure 5d ). Antibodies to these viruses can cause increased infection of these cells by enhancing their uptake without inactivating the virus. Antibody-directed enhancement (ADE) of infection can also occur following natural infection and is understood to be caused by an antibody response unusually dominated by non-neutralising antibodies.

A concern for the current development of SARS-CoV-2 vaccines is raising non-neutralising antibodies that could contribute to ADE. Some experimental MERS-CoV vaccines encountered ADE during development, while ADE was reported in SARS-CoV-1 [40]. When dealing with a novel pandemic virus such as SARS-CoV-2, which has not been thoroughly characterised, the safest approach may be to exclude everything but the target antigen. In the case of SARS-CoV-2, this means delivering only the spike protein to avoid generating nonneutralising antibodies directed at other viral proteins. This cautious approach favours the use of vaccines with more strictly defined antigens such as subunit and mRNA/LNPs, rather than live attenuated or inactivated virus vaccine candidates. However, as our understanding of the virus improves, increasing the breadth of coverage across multiple epitopes should be considered. This modern approach, known as 'reverse vaccinology' [41], is particularly suited to LNP vaccine development due to its flexibility; multiple epitopes can be incorporated simply by adding additional mRNA sequences to the formulation. This circumvents the need to recombinantly express and purify each new antigen for each J o u r n a l P r e -p r o o f reformulation and is a major strength of the platform. Outside of the current pandemic, selective incorporation of epitopes may also be useful for avoiding the generation of antibodies which cross-react with human targets. Diseases such as Guillain-Barre syndrome [42] for example, are thought to involve the activity of antibodies reactive against both influenza virus and human proteins. Although such complications are exceedingly rare, eliminating these concerns could further increase the safety and acceptability of vaccines.

For translation of therapeutic mRNA to occur, it must reach the cytosol. LNPs are taken into cells via endocytosis and are typically trafficked into endo/lysosomal compartments where biomolecules like mRNA are rapidly degraded [43] . A key requirement of LNPs is the need to promote delivery of RNA from the endo/lysosomes in a process referred to as endosomal escape. However, our current strategies to induce endosomal escape are extremely inefficient, and LNP-mediated cytosolic delivery has been estimated to be as low as 1-2% [6] . While it is notable that LNP vaccines and therapeutics have demonstrated efficacy despite a low percentage of mRNA reaching the cytosol, the current low efficiency of endosomal escape leaves significant potential for improvement.

Efforts to improve endosomal escape are limited by an incomplete understanding of the mechanisms involved in cytosolic delivery. Part of the challenge in this area arises from our inability to directly measure endosomal escape. Gene knockdown (when studying siRNA) or expression (when studying mRNA) are sometimes used as surrogate measurements of endosomal escape. However, these endpoint measurements are dependent on downstream J o u r n a l P r e -p r o o f processing after endosomal escape occurs. Recent advances in endosomal escape assays are helping to understand cytosolic delivery [44, 45] . These cellular assays can be combined with liposomal leakage assays which can be used to probe the membrane disruption potential of different LNP formulations [46] .

There are a variety of proposed mechanisms by which endosomal escape may occur [44, 47] , however no single proposed mechanism comprehensively explains the behaviour of all endosomal escape materials. Endosomal escape for LNP cargo is thought to largely occur via destabilisation of the endosomal membrane. It has been proposed that cationic lipids in the LNP structure preferentially complex with anionic lipids that are present in the endosomal membrane. The resulting ion pair adopts a 'cone' shape, promoting the formation of hexagonal HII phase structures over the bilayer phase. This disrupts the lipid bilayer structure of the endosome, allowing cargo (in this case, mRNA) to 'escape' into the cytosol [10, 11, 48] .

Optimising the endosomal escape ability of cationic lipids is already a major focus in the field, with both Pfizer/BioNTech and Moderna using proprietary ionisable lipid formulations in their SARS-CoV-2 vaccines (ALC-0315 and SM-102, respectively). Modifying the chemical structure (and therefore properties) of the lipid by altering the hydrophilic head group, hydrophobic lipid chain or linker region can drastically change its endosomal escape capacity [48] . For instance, the degree of saturation of the lipid chain alters the endosomal escape ability of otherwise identical lipid structures [49] . We still do not completely understand the molecular features that promote endosomal escape behaviour in certain cationic lipids. For instance, a pKa range between 6.2 -6.5 for ionisable lipids has been observed to be 'optimal' to induce endosomal escape [50] . However, not all lipids within this the polymers and nucleic acids, improving the stability of the nucleic acid cargo. However, this strong complexation may hinder nucleic acid dissociation from the carrier material (see Section 7). In contrast, poly(propylacrylic acid) (PPAA) is notable among pH-sensitive membrane-disruptive polymers due to its negative charge. As such, it does not complex with nucleic acid cargoes. At endosomal pH, PPAA transitions into an unionised, hydrophobic form and is thought to facilitate release by partitioning into and disrupting the endosomal membrane [52, 53] .

Cell-penetrating peptides (CPPs) are a class of short peptides that are able to translocate across the bilayer membrane without causing it significant damage. While many CPPs have J o u r n a l P r e -p r o o f successfully delivered cargo to the cytosol, their efficiency is low [54] . Recent developments in the field have led to the design of conformationally-constrained CPPs with greater binding affinity for the endosomal membrane, and a resultant improvement in endosomal escape ability [55] .

Another interesting class of materials are dendrimers, polymers with branched monomer units that extend in 'generations' from a central core [56] . Dendrimers have been used in the cellular delivery of large nucleic acid structures such as plasmid DNA [57] . Due to their structure, dendrimers have higher cationic charge density than their linear counterparts, particularly at higher generations. This promotes complexation of nucleic acids and endosomal escape activity (though the exact mechanism is still to be determined).

Complexation with dendrimers is also able to protect nucleic acids from enzymatic degradation, and the dendrimer surface is populated with functional groups that can be readily modified with stealth or targeting moieties.

An important but potentially overlooked facet of cytosolic LNP delivery is release of the mRNA (or other nucleic acid) payload from the LNP carrier. The strong electrostatic interactions between mRNA and cationic lipids are necessary to promote efficient encapsulation of mRNA during formulation. However, this interaction is detrimental to the subsequent disassembly of the LNP during delivery, where mRNA which remains complexed with cationic lipids cannot be translated into protein. It has been proposed that release of negatively charged nucleic acids from cationic LNPs involves displacement of nucleic acids J o u r n a l P r e -p r o o f from the LNPs by anionic lipids present in the endosomal membrane [58, 59] . This displacement occurs because the dual effect of electrostatic interaction of the headgroups and hydrophobic interactions of the side chains [60] is stronger than the sole electrostatic interaction between nucleic acids and cationic lipid. The efficiency of the process is likely quite low and some mRNA will remain complexed to cationic lipids. To control the association of mRNA with ionic lipids during delivery, the ionic lipids used in the LNP must be carefully designed. The pKa of the ionisable lipids in LNPs play an important role in governing release. The 6.2 -6.5 pKa optimal range identified for ionisable lipids in endosomal escape screens is likely related to the strength of the electrostatic interaction and release of nucleic acids from the ionic lipids.

A potential strategy to improve nucleic acid release from LNPs is the use of charge-shifting materials. For instance, hydrolysable ester bonds have been used to conjugate side chains containing cationic tertiary amine groups to a poly(acrylamide) backbone. The initial charge on the resulting polymer is positive, however hydrolysis of the ester bonds causes loss of the cationic amine groups and introduces anionic carboxylate functionality [61] . A similar strategy could be applied to the design of lipids for LNPs. Temporal control over lipid charge will allow effective dissociation from nucleic acids during delivery without compromising the LNP mechanisms that rely on the charge of the ionic lipids.

Increasing the affinity of mRNA/LNPs for APCs may enable the delivery of a greater proportion of mRNA to APCs, and therefore increase the proportion of total antigen being synthesised that is actively being used to generate an immune response. There are many potential benefits to this: a) increased potency of the immune response, b) decreased toxicity Targeting the LNPs to APCs may increase delivery efficiency, leading to greater protectivity and lower dose vaccines. Furthermore, reducing the proportion of non-APC cells transfected may alleviate side effects such as itching and swelling.

A number of promising targets are available on the APC surface that can be used to direct LNP delivery, including C-C chemokine receptors [64] , CD80 [65] , DEC205 and Clec9A [66] . Targeting can be achieved by attaching target-specific antibodies to the LNP carrier. 

There are two types of adverse responses that have been noted in current LNP formulations.

1) Toxicity of the cationic lipids, leading to localised cell death, and 2) immune responses to components of the LNP formulation, especially PEG.

While cationic lipids are an integral part of mRNA/LNP formulations, they also exert cytotoxic effects. The positive charge of the lipid can destabilise the cellular membrane, leading to cell death. Furthermore, cationic lipids have been shown to induce the production of ROS, a key indicator of apoptosis [69, 70] . To combat these issues, pH dependent ionisable lipids and lipid-like materials have been developed [13] . By adjusting the pKa of these lipids, their ionisation states can be environmentally controlled. They are ionised at low pH, allowing us to leverage their charged properties during formulation and upon internalisation into the acidic environment of the endosome (pH ~6.5) [10, 71] . Under systemic conditions (pH ~7.4), they are unionised, reducing the toxicity associated with surface charge and membrane disruption.

Another potentially undesirable response to the vaccine is the generation of an immune response to the LNP carrier. Despite its reputation as an 'inert' shielding particle, there is an established body of research showing that IgM antibodies are raised against PEG in humans.

Due to its GRAS (generally regarded as safe) designation, the use of PEG has become increasingly common in non-therapeutic products such as cosmetics and food. This has led to anti-PEG antibodies being observed in a growing proportion of the population, including those who have never been exposed to a PEG-containing therapeutic [72] . Anti-PEG IgMs promote accelerated blood clearance, leading to the rapid clearance of PEG and therefore PEG-conjugated nanoparticles upon re-administration [73] . This can lead to significant changes in the biodistribution of the therapeutic, simultaneously reducing delivery to the target organ(s) and increasing unwanted accumulation of drug and carrier in others.

Generation of an anti-PEG immune response would preclude the effectiveness of any PEGconjugated therapeutics in the affected patient. This may limit the ability to deliver multiple J o u r n a l P r e -p r o o f doses of LNP-based therapeutics; an increasing concern as more LNP vaccines are developed, and LNPs are increasingly adopted as carrier systems for novel therapeutics.

To overcome undesired PEG-related immunogenicity, alternative 'shielding' can fill a similar role to the current linear PEG system. Shiraishi et al introduced anionic poly(aspartic acid) blocks between PEG chains and the nanoparticle surface to reduce the binding affinity of anti-PEG IgM antibodies to PEG-conjugated nanoparticles [74] . They observed that anti-PEG IgM have much stronger affinity to PEG when conjugated to a hydrophobic surface, rather than PEG alone. Modifying the architecture of PEG to a 'bottlebrush' structure over the traditional linear structure can also reduce its immunogenicity [75] . Modifying the side chain length of these brushes can substantially reduce the binding of both PEG-backbone-selective and PEG-end group-selective IgMs. These strategies, where the architecture of PEG polymers is altered to reduce immunogenicity without replacing the PEG entirely, are appealing due to the existing investment and large body of research that already exists for PEG polymers.

A variety of synthetic, natural, hydrophilic and zwitterionic polymer approaches have been taken when designing novel 'shielding' materials. Polyoxazolines are synthetic hydrophilic lipids that have shown promising stealth properties and low immunogenicity; however, the relative youth of the field limits the available data regarding their in vivo behaviour, particularly in context of lipid-conjugated polyoxazolines as decoration for LNPs [76] .

Zwitterionic materials such poly(carboxybetaine) are other alternative materials to PEG.

Their strong hydration ability confers stealth properties that are potentially even greater than traditional PEG approaches. Furthermore, they contain abundant reactive groups that can be J o u r n a l P r e -p r o o f leveraged for specific properties (e.g. conjugation) and can be prepared as hydrolysable esters with 'transforming' properties upon hydrolysis [77] . As their development has mostly been focussed on use as anti-fouling surface coating materials, there is little research on their use in LNP formulations (or drug delivery systems at large). They are, however, a very promising candidate for next-generation stealth materials, as they provide strong stealth behaviour and other benefits not afforded by PEG.

mRNA/LNPs have shown significant potential to address the rapid outbreak of a global pandemic like COVID-19. The ease and speed at which the mRNA cargo can be formulated with viral antigen without affecting the physical properties of the vaccine has outpaced the development of traditional vaccines. This same quality also allows LNPs to address potential viral mutations which would decrease the efficacy of an initial vaccine formulation. The use of this cutting-edge vaccine technology to address the pandemic has rapidly advanced the field and LNP vaccines are likely to be increasingly adopted for a range of other diseases in the coming years.

While the success of LNPs has been remarkable, there is still significant room to enhance their effectiveness and safety. We have identified a number of areas with significant potential for optimisation. While some of these parameters are specific to the development of viral vaccines, others (protection of mRNA, optimisation of cytosolic delivery, and controlling release of cargo) can also be applied to LNP formulations in a wider context. LNP carriers have already shown promise in a wide range of therapeutic contexts, including cancer treatment [2] and gene therapy [10] . The success of LNP vaccines is likely to draw renewed 

Nanomedicine and the COVID-19 vaccines

mRNA vaccines -a new era in vaccinology

Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems

Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves

Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA

Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape

A guide to vaccinology: from basic principles to new developments

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Phase 2/3 clinical trial evaluating safety, immunogenicity and efficacy of BNT162b2 (Pfizer/BioNTech vaccine

Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility

On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids

Designing liposomal adjuvants for the next generation of vaccines

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Explanations for the high potency of HPV prophylactic vaccines. Vaccine

An efficient method for longterm room temperature storage of RNA

Metal ion-dependent hydrolysis of RNA phosphodiester bonds within hairpin loops. A comparative kinetic study on chimeric ribo/2′-O-methylribo oligonucleotides

Ribozyme speed limits

Synthetic mRNA capping

Eukaryotic 5-methylcytosine (m⁵ C) RNA Methyltransferases: Mechanisms, Cellular Functions, and Links to Disease

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability

Vaccine Adjuvants: from 1920 to 2015 and Beyond

Effector and memory T-cell differentiation: implications for vaccine development

Regulation of memory B and plasma cell differentiation

Pathogen recognition and inflammatory signaling in innate immune defenses

Immunological decisionmaking: how does the immune system decide to mount a helper T-cell response?

Mechanisms of action of adjuvants

How Follicular Dendritic Cells Shape the B-Cell Antigenome

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines

Damage-Associated Molecular Patterns in Inflammatory Diseases

Transcriptional determinants of tolerogenic and immunogenic states during dendritic cell maturation

Differential Activation Profiles of Multiple Transcription Factors During Dendritic Cell Maturation

Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

Antibody-Dependent Enhancement and Zika: Real Threat or Phantom Menace? Frontiers in cellular and infection microbiology

Antibody-dependent enhancement of coronavirus

Rational Vaccine Design in the Time of COVID-19

Molecular mimicry as a mechanism of autoimmune disease

Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics

Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles

A review highlighting the challenges of engineering endosomal escape in nanoparticles

A molecular sensor to quantify the localization of proteins, DNA and nanoparticles in cells

The Late Endosome and Its Lipid BMP Act as Gateways for Efficient Cytosolic Access of the Delivery Agent dfTAT and Its Macromolecular Cargos

The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular Delivery

Rational design of cationic lipids for siRNA delivery

Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids

Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo

A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes

Used a combinatorial lipid library to optimise the composition of LNP and improve gene silencing

pH-Sensitive polymers that enhance intracellular drug delivery in vivo

-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles

Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges

Overcoming Endosomal Entrapment in Drug Delivery

Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy

Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA

Mechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection

Mechanism of oligonucleotide release from cationic liposomes

Evidence of Interlipidic Ion-Pairing in Anion-Induced DNA Release from Cationic Amphiphile−DNA Complexes. Mechanistic Implications in Transfection

Ultrathin Multilayered Films Assembled from "Charge-Shifting" Cationic Polymers: Extended, Long-Term Release of Plasmid DNA from Surfaces

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

A Thermostable mRNA Vaccine against COVID-19

The Specificity of Targeted Vaccines for APC Surface Molecules Influences the Immune Response Phenotype

Targeting and Specific Activation of Antigen-Presenting Cells by Endogenous Antigen-Loaded Nanoparticles Elicits Tumor-Specific Immunity

Targeting dendritic cells: a promising strategy to improve vaccine effectiveness

Pointing in the Right Direction: Controlling the Orientation of Proteins on Nanoparticles Improves Targeting Efficiency

Demonstrates that controlling the orientation of targeting groups on nanoparticles increases cell binding

Engineering the Orientation, Density, and Flexibility of Single-Domain Antibodies on Nanoparticles To Improve Cell Targeting

Induction of apoptosis in macrophages by cationic liposomes

Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine

Interfacing materials science and biology for drug carrier design

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review

Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance

Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties

Drug Delivery Systems Based on Poly(2-Oxazoline)s and Poly(2-Oxazine)s

Ultralow-Fouling, Functionalizable, and Hydrolyzable Zwitterionic Materials and Their Derivatives for Biological Applications

J o u r n a l P r e -p r o o f Highlights: COVID-19 mRNA vaccines demonstrate the potential of LNPs as robust delivery systems  There is scope to improve targeting, cytosolic delivery and stability of LNPs  SARS-CoV-2 vaccines will accelerate LNP use in gene therapy, cancer, other diseases J o u r n a l P r e -p r o o f

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f